Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study aims to evaluate the efficacy and safety of anlotinib plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have previously treated with immunotherapy.
Methods: This retrospective analysis was conducted on 86 previously immunotherapy-treated patients with advanced NSCLC from December 2018 to October 2024 in clinical practice. Those who received anlotinib plus docetaxel were assigned to experimental group (EG, N=43), while those who were treated with docetaxel monotherapy were deemed as control group (CG, N=43) in clinical practice. Efficacy and safety of both regimens were compared with regular follow-up for survival data collection. The primary endpoints included overall survival (OS) and secondary endpoints were progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR).
Results: ORR in the experimental and control groups was 30.2% (95% CI: 17.2-46.1%) and 13.9% (95% CI: 5.3-27.9%), respectively, showing a trend towards significance (=0.069). DCR was significantly higher in the EG at 79.1% (95% CI: 63.9-89.9%) compared to 51.2% (95% CI: 35.5-66.7%) in the CG (=0.007). After a median follow-up of 12.8 and 8.5 months, respectively, the median PFS was 6.5 months (95% CI: 4.08-8.92) in the EG, compared to 2.9 months (95% CI: 2.53-3.27) in the CG (=0.019). The median OS was 13.5 months (95% CI: 10.49-16.51) in the EG, compared to 9.2 months (95% CI: 5.73-12.67) in the CG (=0.007). Adverse events of all grades occurred in 93.0% of patients in the EG and 83.7% in the CG. Grade 3 or above adverse events were detected in 51.2% and 44.2%, respectively, with similar safety profiles between the groups.
Conclusion: Anlotinib plus docetaxel demonstrated preliminary efficacy and a tolerable safety profile in patients with previously immunotherapy-treated advanced NSCLC, providing a potential therapeutic option in the post-immunotherapy setting. The conclusion should be confirmed in prospective clinical trials subsequently.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048712 | PMC |
| http://dx.doi.org/10.2147/IJGM.S521360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of anlotinib combined with docetaxel versus single docetaxel as second-line treatment beside radiotherapy for advanced non-small cell lung cancer: Efficacy and safety.
Pak J Pharm Sci
July 2025
Department of Gastroenterology, The 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, Nanchang, Jiangxi Province, China.
This study compared the efficacy and safety of anlotinib combined with docetaxel versus docetaxel alone in patients with non-small cell lung cancer (NSCLC), assessing overall survival (OS), disease control rate (DCR), and incidence of adverse events (AE). 128 patients with advanced non-small cell lung cancer were randomly divided into ACD group (n=64) and DOC group (n=64). They were treated with ACD and Docetaxel alone, respectively.
View Article and Find Full Text PDFLong-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report.
Front Immunol
July 2025
Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, China.
Background: Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive subtype of lung cancer with neuroendocrine features, typically diagnosed at an advanced stage. Its clinical presentation and treatment response resemble those of small cell lung cancer, whereas its histological characteristics are more similar to those of non-small cell lung cancer. The rarity and heterogeneity of PLCNEC have impeded the development of standardized treatment protocols.
View Article and Find Full Text PDFImmune checkpoint inhibitors combined with targeted therapy for long-term survival in advanced pulmonary squamous cell carcinoma after first-line failure: A case report and literature review.
Medicine (Baltimore)
June 2025
Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China.
Rationale: Advanced squamous cell carcinoma (SCC) of the lung remains a major clinical challenge due to limited therapeutic options, particularly in the post-immunotherapy setting. Combining immune checkpoint inhibitors with small-molecule multi-targeted tyrosine kinase inhibitors that include anti-angiogenic effects offers a promising approach to overcome treatment resistance and improve survival outcomes.
Patient Concerns: A 44-year-old female with a 2-year history of recurrent cough and sputum production presented with worsening symptoms over the past month, including increased cough frequency and sputum volume.
Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis.
Pharmaceuticals (Basel)
April 2025
Department of Histology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
: Anlotinib is a novel oral antiangiogenic tyrosine kinase inhibitor (TKI) approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC). However, its efficacy in combination with docetaxel remains incompletely understood. Given the need for effective second-line therapies after platinum-based chemotherapy, this systematic review aims to evaluate the therapeutic potential of anlotinib plus docetaxel in advanced NSCLC.
View Article and Find Full Text PDFAnlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial.
Cancer
May 2025
Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: The combination of anlotinib with chemotherapy has demonstrated encouraging efficacy in the treatment of nonsmall cell lung cancer (NSCLC). The objective of this phase 1/2 trial was to establish the maximum tolerated dose of anlotinib in combination with docetaxel and to assess the efficacy and safety of this regimen in patients with advanced NSCLC who had progressed after platinum-based chemotherapy.
Methods: In the phase 1 trial, eight patients were enrolled to determine the maximum tolerated dose, which was identified as 10 mg for anlotinib in combination with docetaxel.